Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Non-GAAP cost of sales by Year
Non-GAAP cost of sales ($M) ($M)
Vertex Pharmaceuticals Non-GAAP cost of sales: $1,620M in FY2025, up 7.8% from a year earlier. That is the highest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Non-GAAP cost of sales | $ | 457.7 | $ | 416.3 | $ | 1,620.0 | $ | 1,502.8”
Source: Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP cost of sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,620 | +7.8% | Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 1,503 | +19.9% | Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 1,253 | +17.0% | Form 8-K (ex-991_q42024.htm, filed 2025-02-10) ↗ |
| FY2022 | Dec 31, 2022 | 1,071 | +19.3% | Form 8-K (ex-991_q42023.htm, filed 2024-02-05) ↗ |
| FY2021 | Dec 31, 2021 | 898 | +22.9% | Form 8-K (ex-991_q42022.htm, filed 2023-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 731 | +38.6% | Form 8-K (ex-991_q42021.htm, filed 2022-01-26) ↗ |
| FY2019 | Dec 31, 2019 | 527 | +30.2% | Form 8-K (ex-991_q42020.htm, filed 2021-02-01) ↗ |
| FY2018 | Dec 31, 2018 | 405 | +47.2% | Form 8-K (ex-991q42019.htm, filed 2020-01-30) ↗ |
| FY2017 | Dec 31, 2017 | 275 | – | Form 8-K (ex-991_q42018.htm, filed 2019-02-05) ↗ |
Cite this data
StockData. (2026). Vertex Pharmaceuticals Non-GAAP cost of sales ($M), annual FY2017–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-cogs
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.